

4. The peptide according to claim 1, wherein the amino acid at the C-terminus of the peptide is amidated.

5. The peptide according to claim 1, wherein the peptide further comprises a reversible modification that increases its bioavailability and facilitates its permeation through the blood brain barrier and epithelial tissue.

6. An isolated nucleic acid sequence encoding a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3.

A1
Conce

7. The nucleic acid sequence according to claim 6, wherein said nucleic acid is selected from the group consisting of bicatenary DNA, monocatenary DNA and RNA.

10. A cell which expresses a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3.

11. A mixture of peptides comprising:

A2

a) at least a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3; and

b) at least a peptide having an amino acid sequence consisting of 3 to 30 contiguous amino acids of SEQ. ID. NO. 4.

12. A mixture according to claim 11, comprising:

a) at least a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3; and

b) at least a peptide having an amino acid sequence selected from the group consisting of amino acid sequence of SEQ. ID. NO. 5 and the amino acid sequence of SEQ. ID. NO. 6.

13. A cosmetic composition comprising

a cosmetically effective amount of a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3 and

a cosmetically acceptable adjuvant.

14. The cosmetic composition according to claim 13, which further comprises, one or more peptides having an amino acid sequence consisting of 3 to 30 contiguous amino acids of SEQ. ID. NO. 4.

15. A method of treating face wrinkles and/or facial asymmetry comprising

applying a cosmetic composition comprising a cosmetically effective amount of a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3 and a cosmetically acceptable adjuvant.

16. A pharmaceutical composition comprising

AJ
a therapeutically effective amount of a peptide having an amino acid sequence selected from the group consisting of amino acid sequence of SEQ. ID. NO. 2 and the amino acid sequence of SEQ. ID. NO. 3 and

a pharmaceutically acceptable excipient.

17. The pharmaceutical composition according to claim 16, which farther comprises, one or more peptides having an amino acid sequence consisting of 3 to 30 contiguous amino acids of SEQ. ID. NO. 4.

18. The pharmaceutical composition according to claim 16, which further comprises, a drug selected from the group consisting of a neuronal glutamate receptor blocker, a calcium chelating agent, an antioxidant, a free radical scavenger and mixtures thereof.

19. The pharmaceutical composition according to claim 18, which further comprises one or more peptides having an amino acid sequence consisting of 3 to 30 contiguous amino acids of SEQ. ID. NO. 4.

20. A pharmaceutical composition comprising

a therapeutically effective amount of a vector comprising a nucleic acid sequence encoding a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3 and

an adjuvant or a pharmaceutically acceptable excipient, or a mixture thereof.

21. A method of treating a disease and/or disorder mediated by pathological neuronal exocytosis comprising

administering a pharmaceutical composition comprising a therapeutically effective amount of a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3 and a pharmaceutically acceptable excipient or an adjuvant or a mixture thereof.

22. A method of treating a disease and/or disorder mediated by pathological neuronal exocytosis, comprising

administering a pharmaceutical composition comprising a therapeutically effective amount of a vector comprising a nucleic acid sequence encoding a peptide having an amino acid sequence selected from the amino acid sequence of SEQ. ID. NO. 2 or the amino acid sequence of SEQ. ID. NO. 3, and an adjuvant or a pharmaceutically acceptable excipient, or a mixture thereof.

Please add new claim 23 as follows:

23. The pharmaceutical composition according to claim 18, further comprising one or more neuronal exocytosis inhibitors.